The Cost and Public Health Burden of Invasive Meningococcal Disease Outbreaks: A Systematic Review

被引:23
|
作者
Anonychuk, Andrea [1 ,2 ,3 ]
Woo, Gloria [4 ]
Vyse, Andrew [1 ]
Demarteau, Nadia [1 ]
Tricco, Andrea C. [5 ]
机构
[1] GlaxoSmithKline Vaccines, Wavre, Belgium
[2] Abbott Labs, Div Diagnost, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Div Diagnost, Mississauga, ON L5N 3R3, Canada
[4] Univ Toronto, Toronto Hlth Econ & Technol Assessment Collaborat, Toronto, ON, Canada
[5] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada
关键词
NEISSERIA-MENINGITIDIS; CONJUGATE VACCINE; UNITED-STATES; SEROGROUP; IMMUNOGENICITY; POLYSACCHARIDE; SAFETY; W-135; INFECTION; ENGLAND;
D O I
10.1007/s40273-013-0057-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background Invasive meningococcal disease (IMD) is a serious disease with a rapid onset, high mortality rate, and risk of long-term complications. Numerous reports in the literature conclude that IMD outbreaks are associated with substantial costs to society and significant burden on communities due to the cost associated with the prevention of secondary cases. Objective To systematically review the literature on the costs and public health burden associated with IMD outbreaks. Methods Studies were primarily identified through searching MEDLINE and EMBASE. Reports were included if they provided cost data related to the containment of an IMD outbreak after 1990 and were written in English, French, or Spanish. Costs were converted to 2010 United States dollars. Outbreaks were categorized by low-income countries (LIC) and high-income countries (HIC) based on gross domestic product per capita. Outbreak containment strategies were classified as small (e.g., targeting members of the school/institution where the outbreak occurred) or large (e.g., targeting everyone in the community). Results Sixteen articles reporting data on 93 IMD outbreaks fulfilled the eligibility criteria and were included. The majority of outbreaks occurred in HIC. Five studies reported the use of small containment strategies including targeted vaccination and chemoprophylaxis, all occurring in HIC. The average cost per small containment strategy was $299,641 and the average cost per IMD case was $41,857. Eight studies reported large containment strategies involving widespread vaccination targeting a specific age group or community. For HIC, the average cost per large containment strategy was $579,851 and the average cost per IMD case was $55,755. In LIC, the average cost per large containment strategy was $3,407,590 and the average cost per IMD case was $2,222. Conclusion IMD outbreaks were associated with substantial costs. We found that although there were numerous reports on IMD outbreaks, data on containment costs were very limited. More research in this area is warranted.
引用
收藏
页码:563 / 576
页数:14
相关论文
共 50 条
  • [41] Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States
    Shah, Hiral Anil
    Jutlla, Ginita
    Herrera-Restrepo, Oscar
    Graham, Jonathan
    Hicks, Katherine A.
    Carrico, Justin
    Grace, Mei
    Clements, Diana E.
    Burman, Cindy
    Sohn, Woo-Yun
    Kuylen, Elise
    Begum, Shahina
    Kocaata, Zeki
    PHARMACOECONOMICS, 2025, 43 (03) : 311 - 329
  • [42] A database study of clinical and economic burden of invasive meningococcal disease in France
    Huang, Liping
    Fievez, Stephane
    Goguillot, Melanie
    Marie, Lucile
    Benard, Steve
    Elkaim, Anne
    Htar, Myint Tin Tin
    PLOS ONE, 2022, 17 (04):
  • [43] Invasive meningococcal disease burden and prophylaxis: update on serogroup B vaccination
    Caceres, Rosario
    Guillen, Jaume
    Gonzalez-Inchausti, Carmen
    Gomez Sobrino, Mamen
    FARMACEUTICOS COMUNITARIOS, 2021, 13 (04): : 28 - 42
  • [44] The Burden of Pediatric Invasive Meningococcal Disease in Spain (2008-2013)
    Rivero-Calle, Irene
    Vilanova-Trillo, Lucia
    Pardo-Seco, Jacobo
    Blanco Salvado, Lidia
    Illade Quinteiro, Laura
    Martinon-Torres, Federico
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (04) : 407 - 413
  • [45] Nigeria's public health response to disease outbreaks: A review of strengths and weaknesses
    Jonah, Japhet H.
    Samuel, Gabriel
    Abdullahi, Mohammed I.
    Emmanuel, Edwin A.
    Danladi, Samuel S.
    Ekwuluo, Celestine E.
    JOURNAL OF PUBLIC HEALTH IN AFRICA, 2024, 15 (01)
  • [46] Meningococcal disease in the Philippines: A systematic review of the literature
    Raguindin, P. F.
    Rojas, V. M.
    Lopez, A. L.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 101 : 149 - 150
  • [47] Range of Clinical Manifestations Caused by Invasive Meningococcal Disease Due to Serogroup W: A Systematic Review
    Bertrand-Gerentes, Isabelle
    Fanchon, Laurent
    Coste, Florence
    Glover, Richard E.
    Guiddir, Tamazoust
    Taha, Muhamed-Kheir
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (10) : 2337 - 2351
  • [48] Range of Clinical Manifestations Caused by Invasive Meningococcal Disease Due to Serogroup W: A Systematic Review
    Isabelle Bertrand-Gerentes
    Laurent Fanchon
    Florence Coste
    Richard E. Glover
    Tamazoust Guiddir
    Muhamed-Kheir Taha
    Infectious Diseases and Therapy, 2023, 12 : 2337 - 2351
  • [49] Guideline review: management of invasive meningococcal disease, SIGN
    Balumer, J. H.
    ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION, 2009, 94 (02): : 46 - 49
  • [50] Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis
    McMillan, Mark
    Chandrakumar, Abira
    Wang, Hua Lin Rachael
    Clarke, Michelle
    Sullivan, Thomas R.
    Andrews, Ross M.
    Ramsay, Mary
    Marshall, Helen S.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (03) : E609 - E619